GlassScriptPhysician profile
Michael L Weiss
NPI 1154350684
$12,100.40
in general payments reported to CMS, 2019-2025
60 companies · $2,272 in 2025
The $2,272 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,819 · 2020: $581 · 2021: $651 · 2022: $1,498 · 2023: $2,088 · 2024: $2,191 · 2025: $2,272.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,531 · Education: $19.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,530.81 |
| Education | $19.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $1,397.90 | 2019-2025 | Apretude, Dovato, Cabenuva |
| Abbvie INC. | $1,307.20 | 2021-2025 | Ubrelvy, Linzess, Vraylar |
| Astrazeneca Pharmaceuticals LP | $1,006.44 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $742.70 | 2019-2025 | Evenity, Prolia, Otezla |
| Gilead Sciences, INC. | $723.64 | 2019-2025 | |
| Lilly USA, LLC | $516.69 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $441.95 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Merck Sharp & Dohme LLC | $414.17 | 2019-2024 | Pifeltro, Delstrigo, Dificid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $366.26 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Pfizer INC. | $352.06 | 2019-2025 | |
| Glaxosmithkline, LLC. | $306.34 | 2019-2025 | Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $275.26 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $275.06 | 2019-2024 | Trintellix |
| Biohaven Pharmaceuticals, INC. | $271.16 | 2021 | |
| Allergan, INC. | $242.45 | 2019-2020 |
Show all 59 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Weiss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.